scholarly journals RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS

2018 ◽  
Vol 10 (3) ◽  
pp. 77-83
Author(s):  
S. V. Zhavoronok ◽  
V. R. Gutmane ◽  
T. M. Baryash ◽  
O. V. Soldatenko ◽  
T. V. Znovets ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Repeated Treatment ◽  
Chain Reaction ◽  
Highly Sensitive ◽  
Sensitive Polymerase Chain Reaction ◽  
Polymerase Chain

To evaluate the efficacy of therapy with sofosbuvir in combination with ledipasvir or daclatasvir, the results of treatment of 299 patients with chronic hepatitis C, including 128 non-responders to combined interferon plus ribavirin therapy, who have prognostically unfavorable single nucleotide polymorphisms 39743165T> G (rs8099917) and 39738787C> T (rs12979860) of interleukin-28B gene, were analyzed. 57 people had liver cirrhosis. 80,9% (242) had genotype 1 of hepatitis C virus, 5% (15) – genotype 2, 13,7% (41) – genotype 3, and 0,4% (1) – genotype 4.All 299 patients, who adhered to the recommendations of the European Association for the Study of the Liver 2016 and the American Association for the Study of the Liver Disease 2017, achieved a sustained virologic response 12 weeks after the end of therapy. The clinical case of treatment failure, associated with the lack of confirmation of the elimination of hepatitis C virus by means of highly sensitive polymerase chain reaction methods and with the later identified amino acid substitution in position Y93H of NS5A (resistance to NS5A inhibitors), is shown.It is necessary to carry out monitoring of effectiveness of therapy only by means of highly sensitive polymerase chain reaction (from 10 ME/ml). If the virus elimination delays in patients with advanced stages of liver fibrosis it is needed to use the prolonged schemes of treatment. Repeated treatment of patients with existence of a mutation of Y93H requires the use of new NS5A inhibitors or combined drugs.

scholarly journals Different PEGylated Interferon Ribavirin Therapy in Non-Responders with Chronic Hepatitis C Virus Infection

2012 ◽  
Vol 2 (2) ◽  
pp. 9-13
Author(s):  
Hisham O. Akbar
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Chain Reaction ◽  
Chronic Hepatitis C Virus ◽  
Polymerase Chain

Background: PEGylated interferon and ribavirin therapy is the current standard of care for patients with chronic Hepatitis C virus. It is unknown whether retreatment may be beneficial in non-responders. Methods: Patients who failed to respond to either PEG-Intron or Pegasys with ribavirin were switched to a different PEGylated interferon with ribavirin. Patients were assessed for virologic response by a decrease in viral load levels using a polymerase chain reaction assay. Only patients who had a negative viral load at week 24 were allowed to continue treatment for 48 weeks. Patients with a negative polymerase chain reaction assay after 6 months off treatment were considered as responders to the retreatment regimen. Results: A total of 16 patients were retreated. The combination of Pegasys and ribavirin was administered to 3 patients, and 13 patients received PEG-Intron with ribavirin. Patients had either genotype 1 or 4. Only 4 patients responded to retreatment with PEG-Intron (25%). The responders were female, had a low viral load and had an early significant viral load reduction. Three patients had genotype 4, and one had genotype 1. Conclusion: Retreatment with different PEGylated interferon in patients who failed previous treatment may have a role in the selected patients infected with chronic Hepatitis C virus.

scholarly journals Antiviral Effect of Interferon Therapy for Patients with Chronic Hepatitis C

1992 ◽  
Vol 3 (5) ◽  
pp. 305-309 ◽  
Author(s):  
J. Hayashi ◽  
K. Nakashima ◽  
A. Noguchi ◽  
M. Hirata ◽  
K. Akazawa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Effect ◽  
Hcv Rna ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Lymphoblastoid Interferon

Thirty-two patients with chronic hepatitis who were positive for hepatitis C virus (HCV) RNA by polymerase chain reaction and had antibody to HCV (anti-HCV), were enrolled in this study. Twenty of them were also positive for antibody to the GOR epitope (anti-GOR). Sixteen of the enrolled patients were treated with human lymphoblastoid interferon for six months. Treatment was initiated with 3 million units of interferon daily for 2 weeks, followed by 3 million units three times a week for 6 weeks and 1.5 million units three times a week for 16 weeks. The efficacy of therapy was assessed by comparison with the results in 16 untreated patients. Aminotransferase values, titre of anti-HCV and anti-GOR antibodies showed significant decreases throughout the therapy compared with baseline levels and the untreated patients. After a 3 month follow-up, nine treated patients (56.3%) had normal aminotransferase activities and six of them eliminated HCV RNA from their sera (37.5%). Three of these six patients became negative for both anti-HCV and anti-GOR antibodies (18.8%). None of the untreated control patients had normal aminotransferase activities or became negative for HCV markers. The present study suggests that human lymphoblastoid interferon can control the disease activity and eliminate hepatitis C virus from patients with chronic hepatitis C.

Diagnosis of chronic hepatitis C after liver transplantation by the detection of viral sequences with polymerase chain reaction

Hepatology ◽  
1992 ◽  
Vol 15 (1) ◽  
pp. 42-45 ◽  
Author(s):  
John J. Poterucha ◽  
Jorge Rakela ◽  
Lawrence Lumeng ◽  
Chao-Hung Lee ◽  
Howard F. Taswell ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Viral Sequences
Sign in / Sign up

Export Citation Format

Share Document